Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer
Anna S. Berghoff(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Guenther G. Steger(Mount Vernon Hospital), Margaretha Rudas(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Christoph Zielinski(Vienna General Hospital), Ursula Pluschnig(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Christoph Wiltschke(University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group)
Cited by 17
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k